Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.54 USD
-0.04 (-2.53%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.54 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Milestone Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -59.69 | -58.39 | -42.85 | -49.97 | -55.23 |
Depreciation/Amortization & Depletion | 0.09 | 0.09 | 0.09 | 0.10 | 0.04 |
Net Change from Assets/Liabilities | 1.24 | -3.26 | 2.26 | -5.81 | 2.85 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.93 | 9.09 | 7.28 | 4.95 | 1.19 |
Net Cash From Operating Activities | -46.42 | -52.47 | -33.22 | -50.73 | -51.15 |
Property & Equipment | -0.11 | -0.27 | 0.00 | 0.00 | -0.41 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.87 | -56.85 | 70.00 | -70.00 | 0.03 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.76 | -57.12 | 70.00 | -70.00 | -0.38 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.58 | 3.09 | 5.06 | 73.22 | 85.41 |
Issuance (Repayment) of Debt | 50.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.79 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 47.79 | 3.09 | 5.06 | 73.22 | 85.41 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 6.12 | -106.51 | 41.83 | -47.51 | 33.87 |
Cash at Beginning of Period | 7.64 | 114.14 | 72.31 | 119.82 | 85.95 |
Cash at End of Period | 13.76 | 7.64 | 114.14 | 72.31 | 119.82 |
Diluted Net EPS | -1.39 | -1.38 | -1.02 | -1.70 | -3.50 |
Fiscal Year End for Milestone Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -59.69 | -46.07 | -30.99 | -14.95 |
Depreciation/Amortization & Depletion | NA | 0.09 | 0.07 | 0.04 | 0.02 |
Net Change from Assets/Liabilities | NA | 1.24 | 0.11 | 1.67 | -1.22 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 11.93 | 9.28 | 4.81 | 2.24 |
Net Cash From Operating Activities | NA | -46.42 | -36.63 | -24.47 | -13.90 |
Property & Equipment | NA | -0.11 | -0.08 | -0.06 | -0.03 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 4.87 | -8.84 | 2.00 | 30.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 4.76 | -8.92 | 1.94 | 29.97 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.58 | 0.58 | 0.28 | 0.25 |
Issuance (Repayment) of Debt | NA | 50.00 | 50.00 | 50.00 | 50.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -2.79 | -2.79 | -2.79 | 0.00 |
Net Cash from Financing Activities | NA | 47.79 | 47.79 | 47.49 | 50.25 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 6.12 | 2.24 | 24.96 | 66.32 |
Cash at Beginning of Period | NA | 7.64 | 7.64 | 7.64 | 7.64 |
Cash at End of Period | NA | 13.76 | 9.88 | 32.59 | 73.95 |
Diluted Net EPS | NA | -0.32 | -0.35 | -0.37 | -0.35 |